Cargando…

Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy

OBJECTIVE: To explore the potential of neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) as biomarkers of spinal cord degeneration in adrenoleukodystrophy, as objective treatment‐outcome parameters are needed. METHODS: Plasma NfL and GFAP levels were measured in 45 male and 47 fem...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Ballegoij, Wouter J. C., van de Stadt, Stephanie I.W., Huffnagel, Irene C., Kemp, Stephan, Willemse, Eline A. J., Teunissen, Charlotte E., Engelen, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664277/ https://www.ncbi.nlm.nih.gov/pubmed/33047897 http://dx.doi.org/10.1002/acn3.51188

Ejemplares similares

Spinal cord atrophy as a measure of severity of myelopathy in adrenoleukodystrophy
por: van de Stadt, Stephanie I. W., et al.
Publicado: (2020)

Postural Body Sway as Surrogate Outcome for Myelopathy in Adrenoleukodystrophy
por: van Ballegoij, Wouter J. C., et al.
Publicado: (2020)

Magnetic resonance spectroscopy as marker for neurodegeneration in X-linked adrenoleukodystrophy
por: van de Stadt, Stephanie I.W., et al.
Publicado: (2021)

Optical coherence tomography to measure the progression of myelopathy in adrenoleukodystrophy
por: van Ballegoij, Wouter J. C., et al.
Publicado: (2021)

Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels
por: Camara-Lemarroy, Carlos, et al.
Publicado: (2022)

Optical coherence tomography shows neuroretinal thinning in myelopathy of adrenoleukodystrophy
por: van Ballegoij, Wouter J. C., et al.
Publicado: (2019)

Correction to: Optical coherence tomography shows neuroretinal thinning in myelopathy of adrenoleukodystrophy
por: van Ballegoij, Wouter J. C., et al.
Publicado: (2020)

Molecular Biomarkers for Adrenoleukodystrophy: An Unmet Need
por: Honey, Madison I. J., et al.
Publicado: (2021)

A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort
por: van Dam, Maureen, et al.
Publicado: (2023)

Disease progression in women with X-linked adrenoleukodystrophy is slow
por: Huffnagel, Irene C., et al.
Publicado: (2019)

Emergence delirium and postoperative delirium associated with high plasma NfL and GFAP: an observational study
por: Liu, Xingyang, et al.
Publicado: (2023)

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
por: Barro, Christian, et al.
Publicado: (2022)

Sex Differences in Behavioral Symptoms and the Levels of Circulating GFAP, Tau, and NfL in Patients With Traumatic Brain Injury
por: Sass, Dilorom, et al.
Publicado: (2021)

International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach
por: Engelen, Marc, et al.
Publicado: (2022)

Neurochemical Monitoring of Traumatic Brain Injury by the Combined Analysis of Plasma Beta-Synuclein, NfL, and GFAP in Polytraumatized Patients
por: Halbgebauer, Rebecca, et al.
Publicado: (2022)

Quantification and prospective evaluation of serum NfL and GFAP as blood-derived biomarkers of outcome in acute ischemic stroke patients
por: Ferrari, Federica, et al.
Publicado: (2023)

Evolution of adrenoleukodystrophy model systems
por: Montoro, Roberto, et al.
Publicado: (2021)

Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias
por: Baiardi, Simone, et al.
Publicado: (2022)

Effect of Estimated Blood Volume and Body Mass Index on GFAP and NfL Levels in the Serum and CSF of Patients With Multiple Sclerosis
por: Yalachkov, Yavor, et al.
Publicado: (2022)

GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients
por: Gust, Juliane, et al.
Publicado: (2022)

Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
por: Schindler, Patrick, et al.
Publicado: (2021)

Overall intact cognitive function in male X-linked adrenoleukodystrophy adults with normal MRI
por: Buermans, Noortje J. M. L., et al.
Publicado: (2019)

Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19
por: Bark, Lovisa, et al.
Publicado: (2023)

Bezafibrate for X-Linked Adrenoleukodystrophy
por: Engelen, Marc, et al.
Publicado: (2012)

Plasma UCHL1, GFAP, Tau, and NfL Are Not Different in Young Healthy Persons With Mild COVID-19 Symptoms Early in the Pandemic: A Pilot Study
por: Rogatzki, Matthew J., et al.
Publicado: (2023)

NfL and pNfH are increased in Friedreich’s ataxia
por: Hayer, Stefanie Nicole, et al.
Publicado: (2020)

Attitudes of Patients with Adrenoleukodystrophy towards Sex-Specific Newborn Screening
por: Yska, Hemmo A. F., et al.
Publicado: (2023)

Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting
por: Youssef, Priscilla, et al.
Publicado: (2023)

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study: Serum NfL predicts relapse-free progression
por: Uphaus, Timo, et al.
Publicado: (2021)

Sex‐specific newborn screening for X‐linked adrenoleukodystrophy
por: Albersen, Monique, et al.
Publicado: (2022)

NfL as a biomarker for neurodegeneration and survival in Parkinson disease
por: Bäckström, David, et al.
Publicado: (2020)

Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor
por: Barendsen, Rinse W., et al.
Publicado: (2020)

X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management
por: Engelen, Marc, et al.
Publicado: (2012)

Structure and Function of the ABCD1 Variant Database: 20 Years, 940 Pathogenic Variants, and 3400 Cases of Adrenoleukodystrophy
por: Mallack, Eric J., et al.
Publicado: (2022)

C26:0-Carnitine Is a New Biomarker for X-Linked Adrenoleukodystrophy in Mice and Man
por: van de Beek, Malu-Clair, et al.
Publicado: (2016)

Corrigendum: Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor
por: Barendsen, Rinse W., et al.
Publicado: (2021)

Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticus
por: Margraf, Nils G., et al.
Publicado: (2023)

The Use of Biologics in NFL Athletes: An Expert Consensus of NFL Team Physicians
por: Murray, Iain R., et al.
Publicado: (2023)

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
por: Hansson, Oskar, et al.
Publicado: (2017)

Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria
por: Kern, Daniela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7jdojneuko3trce4n0nf37am5o